Highlights:
- Using the clinically developed compstatin family of C3 inhibitors and periodontitis as illustrative examples, this review highlights emerging therapeutic concepts and developments in the design of C3-targeted drug candidates as novel immunotherapeutics for oral and systemic inflammatory diseases.
Author and source information
Authors: Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD.
Reference: Mol Oral Microbiol. 2016 Feb;31(1):3-17. doi: 10.1111/omi.12129. Epub 2015 Oct 7.
Source: www.ncbi.nlm.nih.gov